EUVIMEDEUVIMED entdecken
Crossref

2712-LB: Sensory Function Improvement Demonstrated with 10-kHz Spinal Cord Stimulation (SCS) in Painful Diabetic Neuropathy (PDN)

ELIAS S. SIRAJ, ROBERT W. HURLEY, SHAWN M. SILLS, RODICA POP-BUSUI, DAVID ARMSTRONG, ANDREW J. BOULTON, QUANG NGUYEN, BRIAN L. LEVY, SOLOMON TESFAYE, GEORGE GRUNBERGER, ERIKA A. PETERSEN, SAMER NAKHLE und 4 weitere

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-2712-lb ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von ELIAS S. SIRAJ und 15 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: Individuals with PDN experience substantial reductions in quality of life due to both pain and loss of sensory function. A multicenter RCT evaluated the effectiveness of 10kHz SCS plus conventional medical management (CMM) versus CMM alone for improving pain and sensory function in people with PDN.

Methods

Eligible PDN participants with lower-limb pain ≥5 cm on a 10-cm visual analog scale and sensory loss defined by a modified Toronto Neuropathic Clinical Score (mTNCS) >5 were randomized 1:1 to receive 10kHz-SCS (Nevro Corp.) or CMM alone (NCT05777317). The key endpoints were pain responder rate (≥50% pain relief) and sensory improvement of ≥3 mTNCS points, assessed by an allocation-blinded evaluator. Participants could cross over to the alternate treatment after 6 months (6M), with follow-up of 12 months (12M).

Results

Of 91 randomized participants, 50 were assigned to CMM and 41 to SCS. At 6M both the pain (P<0.0001) and the sensory (P=0.014) responder rate endpoints were met. None of the SCS group crossed over to CMM, while 92% of the CMM crossed over to SCS treatment. One explant (1.4%) occurred for implant site pain, with none for lack of efficacy. Improvements in both sensory function and pain were significant and sustained at 12 M, including crossovers (Figure 1).

Conclusion

The study provides the first prespecified evidence of significant sensory function improvement in PDN participants using 10kHz SCS. Disclosure E.S. Siraj: Speaker's Bureau; Current; Boehringer Ingelheim International GmbH. Research Support; Current; Boehringer Ingelheim International GmbH. Speaker's Bureau; Current; Novo Nordisk. Consultant; Current; Novo Nordisk. Consultant; Ended; Eli Lilly and Company. Consultant; Current; Nevro Corp. R.W. Hurley: Research Support; Current; Nevro Corp. Consultant; Current; State Farm Insurance. Research Support; Current; National Institutes of Health. S.M. Sills: Research Support; Current; Nevro Corp. R. Pop-Busui: Board Member; Current; American Diabetes Association. Consultant; Current; Averitas Pharma, Inc. Research Support; Current; Bayer AG. Consultant; Current; Lexicon Pharmaceuticals, Inc. Research Support; Current; National Institutes of Health. Consultant; Current; Novo Nordisk, Roche Diagnostics, Vertex Pharmaceuticals Incorporated. Consultant; Ended; Viatris Inc. D. Armstrong: None. A.J. Boulton: None. Q. Nguyen: None. B.L. Levy: Advisory Panel; Current; Nevro Corp., CeQur SA. S. Tesfaye: Advisory Panel; Current; AstraZeneca, Nevro Corp. Speaker's Bureau; Current; Novo Nordisk, Viatris Inc., Medtronic. Advisory Panel; Current; Bayer AG, Wörwag Pharma GmbH & Co. KG. Advisory Panel; Ended; Procter & Gamble, Grünenthal Group. G. Grunberger: Speaker's Bureau; Current; Abbott Diabetes, Eli Lilly and Company. Advisory Panel; Current; MannKind Corporation, Vertex Pharmaceuticals Incorporated. E.A. Petersen: Consultant; Current; Nevro Corp., Biotronik, Saluda Medical, Medtronic. Other - sponsored research at institution; Ended; Nevro Corp. Other - sponsored research at institution; Current; Saluda Medical, ShiraTronics. Stock/Shareholder; Current; SynerFuse, US Pain Care, Equanimity.ai. S. Nakhle: None. J. Jameson: Consultant; Current; SPR, Boston Scientific Corporation. Consultant; Ended; Nevro Corp., Abbott. M. Guirguis: Consultant; Current; Boston Scientific Corporation, Saluda Medical, Averitas Pharma, Inc., Avanos Medical, Inc. Consultant; Ended; Vertex Pharmaceuticals Incorporated. R. Province-Azalde: Employee; Current; Nevro Corp. D. Caraway: Employee; Current; Nevro Corp.

Zitieren

APA

SIRAJ, E. S., HURLEY, R. W., SILLS, S. M., POP-BUSUI, R., ARMSTRONG, D., BOULTON, A. J., NGUYEN, Q., LEVY, B. L., TESFAYE, S., GRUNBERGER, G., PETERSEN, E. A., NAKHLE, S., JAMESON, J., GUIRGUIS, M., PROVINCE-AZALDE, R., & CARAWAY, D. (2026). 2712-LB: Sensory Function Improvement Demonstrated with 10-kHz Spinal Cord Stimulation (SCS) in Painful Diabetic Neuropathy (PDN). Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2712-lb

Vancouver

SIRAJ ES, HURLEY RW, SILLS SM, POP-BUSUI R, ARMSTRONG D, BOULTON AJ, et al. 2712-LB: Sensory Function Improvement Demonstrated with 10-kHz Spinal Cord Stimulation (SCS) in Painful Diabetic Neuropathy (PDN). Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2712-lb

BibTeX
@article{SIRAJ2026,
  author = {SIRAJ, ELIAS S. and HURLEY, ROBERT W. and SILLS, SHAWN M. and POP-BUSUI, RODICA and ARMSTRONG, DAVID and BOULTON, ANDREW J. and NGUYEN, QUANG and LEVY, BRIAN L. and TESFAYE, SOLOMON and GRUNBERGER, GEORGE and PETERSEN, ERIKA A. and NAKHLE, SAMER and JAMESON, JESSICA and GUIRGUIS, MAGED and PROVINCE-AZALDE, ROSE and CARAWAY, DAVID},
  title = {2712-LB: Sensory Function Improvement Demonstrated with 10-kHz Spinal Cord Stimulation (SCS) in Painful Diabetic Neuropathy (PDN)},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-2712-lb}
}
Kostenlos starten →